Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Nasopharyngeal Carcinoma 18 Esophageal Neoplasms 12 Squamous Cell Carcinoma of Head and Neck 11 Esophageal Squamous Cell Carcinoma 11 Uterine Cervical Neoplasms 9 Head and Neck Neoplasms 9 Carcinoma, Non-Small-Cell Lung 9 Pancreatic Neoplasms 8 Stomach Neoplasms 4 Neoplasms 3 Colorectal Neoplasms 3 Recurrence 2 Pancreatic cancer, adult 2 Neoplasm Metastasis 2 Nasopharyngeal Neoplasms 2 Lung Neoplasms 2 Diffuse Intrinsic Pontine Glioma 2 Carcinoma 2 Adenocarcinoma 2 Uterine Cervical Dysplasia 1 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Anal Canal 1 Solid Tumors 1 Solid Tumor 1 Resectable Pancreatic Cancer 1 Penile Neoplasms 1 Pathologic Complete Response 1 Pancreatic Cancer Resectable 1 Oropharyngeal Neoplasms 1 Nasopharyngeal Diseases 1

Interventions

pembrolizumab 14 Injections 13 Paclitaxel 10 Nivolumab 10 Docetaxel 9 Cisplatin 9 Capecitabine 9 Bevacizumab 8 toripalimab 7 senaparib 7 Fluorodeoxyglucose F18 7 Cyclophosphamide 7 tislelizumab 6 atezolizumab 6 Irinotecan 6 Fluorouracil 6 Gemcitabine 5 fludarabine 4 apatinib 4 Oxaliplatin 4 Leucovorin 4 Ipilimumab 4 spartalizumab 3 pertuzumab 3 olaparib 3 camrelizumab 3 Rifampin 3 Radiosurgery 3 Midazolam 3 Itraconazole 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Solid Tumor × nimotuzumab × Clear all

NCT06022276 2023-09-01

Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors

Tianjin Medical University Second Hospital

Phase NA Unknown

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡